Published secondary patency rates in peripheral graft access after stent placement at 1 year range from 60% to 90% [10–12, 19]. Our results for secondary patency rates are comparable with these. Although peripheral stents allow long-term secondary patency, multiple reinterventions are required to maintain it. Furthermore, more reinterventions may be needed to maintain secondary patency compared with balloon angioplasty alone. Our data indicate that although stent patency was sometimes quite long, stenosis at the stented segment is predictable (78.6%).

The present study had some study limitations. The present study was limited by the small patient population, particularly in the subgroups, and by its retrospective design. There was bias because all patients were Asian with 5-mm-diameter polyurethane grafts. The use of stents might decrease annually due to recent technical improvements in angioplasty. Therefore, the stent usage rate in our study might be higher. The subset analyses were thus weak. Occurrence of indication A was not quantitative because it was decided by visualized restoration of access flow in fistulography and by palpable thrill. Our procedures included angioplasty using cutting balloons, which might not be similar to that using regular balloons. To more accurately determine the effectiveness of stent placement to treat failed balloon angioplasty, stent placement with balloon angioplasty alone after failed balloon angioplasty should be examined in a randomized study.

In conclusion, peripheral stent placement is effective for salvaging hemodialysis access after failed balloon angioplasty. Peripheral stent placement for early (<3 months) recurring stenosis significantly improves primary patency compared with previous angioplasty alone. However, reinterventions were required to maintain secondary patency after stent placement. We emphasize that peripheral stent placement cannot achieve the same primary patency as successful balloon angioplasty without stent placement. We recommend that although peripheral stent placement is effective for failed balloon angioplasty, the success rate of balloon angioplasty needs to be improved to reduce the use of stents.

References

1. Trerotola SO, Stavropoulos SW, Shlansky-Goldberg R, Tuite CM, Kobrin S, Rudnick MR (2004) Hemodialysis-related venous stenosis:treatment with ultrahigh-pressure angioplasty balloons. Radiology 231(1):259–262
2. Kariya S, Tanigawa N, Kojima H et al (2007) Primary patency with cutting and conventional balloon angioplasty for different types of hemodialysis access stenosis. Radiology 243(2):578–587
3. Peregrin JH, Rocek M (2007) Results of a peripheral cutting balloon prospective multicenter European registry in hemodialysis vascular access. Cardiovasc Interv Radiol 30(2):212–215
4. Tsetis D, Morgan R, Belli AM (2006) Cutting balloons for the treatment of vascular stenoses. Eur Radiol 16(8):1675–1683
5. National Kidney Foundation-Dialysis Outcomes Quality Initiative (1997) NKF-DOQI clinical practice guidelines for vascular access. Am J Kidney Dis 30(4 Suppl 3):S150–S191
6. Aruny JE, Lewis CA, Cardella JF et al (1999) Quality improvement guidelines for percutaneous management of the thrombosed or dysfunctional dialysis access. Standards of Practice Committee of the Society of Cardiovascular & Interventional Radiology. J Vasc Interv Radiol 10(4):491–498
7. Gray RJ, Sacks D, Martin LG, Trerotola SO (2003) Reporting standards for percutaneous interventions in dialysis access. J Vasc Interv Radiol 14(9; Pt 2):S433–S442
8. Turmel-Rodrigues LA, Blanchard D, Pengloan J et al (1997) Wallstents and Craggstents in hemodialysis grafts and fistulas: results for selective indications. J Vasc Interv Radiol 8(6):975–982
9. Vogel PM, Parise C (2004) SMART stent for salvage of hemodialysis access grafts. J Vasc Interv Radiol 15(10):1051–1060
10. Sreenarasimhaiah VP, Margassery SK, Martin KJ, Bander SJ (2005) Salvage of thrombosed dialysis access grafts with venous anastomosis stents. Kidney Int 67(2):678–684
11. Maya ID, Allon M (2006) Outcomes of thrombosed arteriovenous grafts: comparison of stents vs. angioplasty. Kidney Int 69(5): 934–937
12. Patel RI, Peck SH, Cooper SG et al (1998) Patency of Wallstents placed across the venous anastomosis of hemodialysis grafts after percutaneous recanalization. Radiology 209(2):365–370
13. Haage P, Vorwerk D, Piroth W, Schuermann K, Guenther RW (1999) Treatment of hemodialysis-related central venous stenosis or occlusion: results of primary Wallstent placement and follow-up in 50 patients. Radiology 212(1):175–180
14. Mickley V, Gorich J, Rilinger N, Storck M, Abendroth D (1997) Stenting of central venous stenoses in hemodialysis patients: long-term results. Kidney Int 51(1):277–280
15. Vorwerk D, Guenther RW, Mann H et al (1995) Venous stenosis and occlusion in hemodialysis shunts: follow-up results of stent placement in 65 patients. Radiology 195(1):140–146
16. Raynaud AC, Angel CY, Sapoval MR, Beyssen B, Pagny JY, Auguste M (1998) Treatment of hemodialysis access rupture during PTA with Wallstent implantation. J Vasc Interv Radiol 9(3):437–442
17. Kolakowski S Jr, Dougherty MJ, Calligaro KD (2003) Salvaging prosthetic dialysis fistulas with stents: forearm versus upper arm grafts. J Vasc Surg 38(4):719–723
18. Cynamon J, Lakritz PS, Wahl SI, Bakal CW, Sprayregen S (1997) Hemodialysis graft declotting: description of the "lyse and wait" technique. J Vasc Interv Radiol 8(5):825–829
19. Beathard GA (1993) Gianturco self-expanding stent in the treatment of stenosis in dialysis access grafts. Kidney Int 43(4): 872–877
20. Quinn SF, Schuman ES, Demlow TA et al (1995) Percutaneous transluminal angioplasty versus endovascular stent placement in the treatment of venous stenoses in patients undergoing hemodialysis: intermediate results. J Vasc Interv Radiol 6(6):851–855
21. Hoffer EK, Sultan S, Herskowitz MM, Daniels ID, Sclafani SJ (1997) Prospective randomized trial of a metallic intravascular stent in hemodialysis graft maintenance. J Vasc Interv Radiol 8(6):965–973
22. Trerotola SO, Ponce P, Stavropoulos SW et al (2003) Physical examination versus normalized pressure ratio for predicting outcomes of hemodialysis access interventions. J Vasc Interv Radiol 14(11):1387–1394

Surgical Results After Preoperative Chemoradiation Therapy for Patients With Pancreatic Cancer

Sohei Satoi, MD, Hiroaki Yanagimoto, MD,* Hideyoshi Toyokawa, MD,* Kanji Takahashi, MD,* Yoichi Matsui, MD,* Hiroaki Kitade, MD,* Hynek Mergental, MD,* Noboru Tanigawa, MD,† Soichiro Takai, MD,* and A-Hon Kwon, MD**

Objectives: The results of surgical therapy alone for pancreatic cancer are disappointing. We explored surgical results after neoadjuvant chemoradiation therapy (NACRT) for patients with pancreatic cancer that extended beyond the pancreas.

Methods: Sixty-eight consecutive patients with pancreatic cancer who underwent pancreatic resection were included. Twenty-seven patients underwent surgical resection after NACRT (NACRT group). The other 41 patients were classified as surgery-alone group. Surgical results were compared in patients who underwent curative resection (R0/1) who were followed up for at least 25 months and underwent no adjuvant therapy.

Results: A lower frequency of lymph node metastasis was observed in the NACRT group ($P < 0.05$). The frequency of residual tumor grading in the NACRT group was significantly different from that in surgery-alone (R0/1/2%, 52/15/33 vs 22/51/27; $P = 0.0040$). In R0/1 cases, overall survival and disease-free survival rates in the NACRT group (n = 18) were significantly longer than in surgery-alone (n = 30, $P < 0.05$). The rate of local recurrence in the NACRT group was significantly less than in surgery-alone (11% vs 47%, $P = 0.0024$).

Conclusions: This single-institution experience indicates that NACRT is able to increase the resectability rate with clear margins and to decrease the rate of metastatic lymph nodes, resulting in improved prognosis of curative cases with pancreatic cancer that extended beyond the pancreas.

Key Words: curative resection, retrospective analysis, gemcitabine, 5-FU, CDDP, survival analysis

(*Pancreas* 2009;38: 282–288)

The results of surgical therapy alone for pancreatic ductal cancer are still disappointing. Surgical resection for patients with pancreatic cancer at an early stage, which corresponds to cancer growth within pancreatic parenchyma, is the only curative treatment option; however, both distant and local/regional patterns of relapse are common within a year, even after curative resection.[1] In approximately 50% of resected pancreatic tumors, the surgical margins contain tumor cells.[2] The aggressive features of pancreatic cancer can lead to a dismal prognosis, and surgery alone is not optimal for achieving locoregional control of pancreatic cancer.[3,4]

To achieve 5-year survival exceeding 50% in patients with pancreatic cancer, Traverso LW advocated appropriate patient selection for curative resection by accurate staging, balanced resection, centralized treatment in high-volume centers, and the use of an effective adjuvant or neoadjuvant therapy.[4] Neoadjuvant (preoperative) chemoradiation therapy (NACRT) has several possibilities such as improved patient selection after the restaging evaluation, increased resectability rate with clear margins (R0 resection),[5] decreased rate of metastatic lymph nodes, and decreased rate of local relapse.[6] We previously reported that preoperative chemoradiation (5-fluorouracil [5-FU] or gemcitabine + 40 Gy) enabled the selection of 24 of 32 patients for surgery and resulted in acceptable toxicity.[7]

The objectives of this retrospective study were to compare the pathological results, overall survival (OS) and disease-free survival (DFS) rates, and type of recurrence in pancreatic cancer patients who underwent surgical resection after NACRT with those of patients who underwent surgery alone.

MATERIALS AND METHODS

One hundred seventy-five consecutive patients with a clinical diagnosis of pancreatic ductal adenocarcinoma were evaluated for the staging of tumor extension between January 2000 and December 2005 in Kansai Medical University Hospital. Cases involving an endocrine tumor of the pancreas, intraductal papillary mucinous cancer, acinar cell cancer, anaplastic cancer, duodenal cancer, distal common bile duct cancer, or ampullary cancer were excluded. During this period, 68 consecutive patients with pancreatic cancer who underwent pancreatic resection were included in this study. All tissues of the resected patients were pathologically proven ductal adenocarcinoma of the pancreas. Between 2001 and 2004, NACRT was performed in 35 patients who had radiologically diagnosed pancreatic cancer that extended beyond the pancreas (T3/T4 pancreatic cancer by TNM staging), and who were regarded as potentially resectable ([PR] n = 19) and locally advanced ([LA] n = 16), defined by National Comprehensive Cancer Network (NCCN) guideline.[8] Treatment consisted of concurrent radiotherapy (40 Gy within 4 weeks), and chemotherapy with 5-FU and cisplatin (CDDP) ([FP] n = 13) or with gemcitabine ([GEM] n = 22), as described in the previous article.[7] Finally, 27 patients (PR, n = 16; LA, n = 11; FP, n = 8; GEM n = 19) underwent surgical resection (NACRT group). The other 41 patients were classified as the surgery-alone group that consisted of pancreatic cancer patients who had a tumor limited to the pancreas (T1/T2 TNM staging) between 2001 and 2004, and the resected cases from 2000 and from 2005. Forty-eight patients with residual tumor staging of R0/1 were abstracted from 68 resected patients between 2000 and 2005, and the clinical and pathological characteristics, OS rate, DFS rate, and type of relapse were compared (NACRT group, n = 18; surgery-alone group, n = 30). All patients were followed up for at least 25 months and underwent no adjuvant chemotherapy.

As shown in the previous article,[9,10] local tumor unresectability was defined as (1) vascular involvement of a major

From the Departments of *Surgery and †Radiology, Kansai Medical University, Hirakata City, Osaka, Japan.
Received for publication April 16, 2008; accepted October 29, 2008.
Reprints: Sohei Satoi, MD, Department of Surgery, Kansai Medical University, 2-3-1 Shin-machi, Hirakata City, Osaka 573-1191, Japan (e-mail: satoi@hirakata.kmu.ac.jp).



FIGURE 1. The regimen of NACRT.



FIGURE 2. Clinical course of the NACRT group. PR indicates potentially resectable; borderline, borderline resectable in the NCCN guidelines.

peripancreatic artery (defined as tumor ingrowth with >50% vessel contiguity in the celiac trunk [CA], common or proper hepatic artery, or superior mesenteric artery); (2) extended obstruction of the portal vein to distal branches of the superior mesenteric vein; or (iii) with cavernous transformation of the porta hepatis. Patients with peritoneal carcinomatosis or distant organ metastasis were also excluded from this study. On the other hand, patients with cancer in the pancreatic body and tail, with CA invasion, and without superior mesenteric artery (SMA) invasion were also classified as candidates for the Appleby operation. All operations were performed by 2 experienced hepatopancreatobiliary surgeons who were in agreement about the extent of surgery to be performed. Preoperative staging was performed using contrast-enhanced computed tomography (CECT), abdominal angiography, CT-assisted hepatic arteriography, and CT during arterial portography before August 2002, and using CE multidetector row CT after September 2002.[9,10]

The detailed eligibility criteria were reported in the previous article.[8] Informed consent was obtained from all patients according to institutional regulations, and this study was approved by the local ethics committee. Patient data were obtained from the prospective database of pancreatic disease at Kansai Medical University Hospital.

Treatment Protocol

Patients received a continuous infusion of 5-FU (200 mg/m^2 5 times per week, 1–4 weeks), accompanied by CDDP (3 mg/m^2 on days 1–5, 6 mg/m^2 on days 9, 12, 14, 19, 23, and 26) in the FP-NACRT arm (Fig. 1). Gemcitabine at a dose of 400 mg/m^{-2} per day was given intravenously over 30 minutes starting 2 hours before radiotherapy 3 times weekly for 4 weeks in the GEM-NACRT arm (Fig. 1). Concomitantly, 10 mg of azasetron was routinely given before chemotherapy administration. Chemoinfusion was started approximately 60 minutes before radiation therapy. The protocol for radiation therapy was as follows. A total of 40 Gy was concurrently delivered in 2-Gy fractions to the tumor bed Monday through Friday for 4 weeks by a linear accelerator using megavoltage photon beams (6 MV). The clinical target volume was delineated slice by slice on the planning CT scan using CT simulation software. It encompassed the gross tumor volume as defined by the preoperative CT scan, plus a margin of 0.8 cm. Also included were retroperitoneal paraaortic lymphatic vessels between the CA and the upper mesenteric artery to the anterior level of the vertebral bodies. The gross tumor volume was defined as the gross tumor mass detected by CT scans. The planning target volume included the clinical target volume, with a 1-cm margin. Usually, a 4-field approach was chosen using anteroposterior and left and right lateral beams.

Surgical resection was performed 3 to 4 weeks after NACRT completion if none of the following were found: disease progression to an unresectable status (as previously mentioned) as determined by repeated abdominal CECT, a prohibitive decline in performance status, or other evidence of metastatic disease. Pancreatectomy was performed with portal vein resection, if portal vein resection was predicted to provide a surgical- or pathological-free margin. For resected patients, curative surgery was performed with extended lymph node dissection including paraaortic lymph nodes. Median time from the last day of NACRT to surgical resection was 28 days (range, 15–60 days). If tumor progression was evident, additional treatment with chemotherapeutic regimens was determined on an individual basis.

TABLE 1. Patient and Operative Factors of the NACRT and Control Groups

	NACRT	Control	P
Total no. patients	27	41	
Age	64 (47–74)	66 (50–83)	n.s.
Gender (male/female)	10:17	23:18	n.s.
CA19-9, U/mL	110 (1–8116)	89.7 (1–9116)	n.s.
Comorbid disease (+/−)	14:13	23:18	n.s.
Site of primary lesion			
Head/body-tail	21:6	28:13	n.s.
Tumor size, mm	30 (16–80)	30 (13–90)	n.s.
CDRS (PR/borderline)	16:11	24:17	n.s.
Type of surgery (PD/TP/DP)	20:1:6	27:1:13	n.s.
PV resection (+/−)	4:23	12:29	n.s.
CA resection (+/−)	2:25	1:40	n.s.
Operative duration, min	560 (325–840)	515 (265–900)	n.s.
Extent of blood loss, mL	1390 (400–6420)	1045 (390–7250)	n.s.

Data are expressed as the median (range).

Borderline indicates borderline resectable; CA19-9, carbohydrate antigen 19-9; CDRS, criteria defining resectability status; DP, distal pancreatectomy; n.s., not significant; PD, pancreaticoduodenectomy; PR, potentially resectable; PV, portal vein; TP, total pancreatectomy.

TABLE 2. Tumor Factors of the NACRT and Control Groups

	NACRT	Control	P
Total no. patients	27	41	
Site of primary lesion			
Head/body-tail	21:6	28:13	n.s.
Tumor size, mm	30 (16–80)	30 (13–90)	n.s.
Pathological differentiation (well/mod/por/other)	6:18:1:2	10:22:5:4	n.s.
Stage I–III : IVa/IVb	10:17	13:28	n.s.
LN mets positive/negative	11:16	28:13	0.0440
INF β/γ	19:8	33:8	n.s.
Ly 0/1:2/3	16:11	13:28	0.0440
V 0/1:2/3	22:5	20:21	0.0102
Ne 0/1:2/3	7:20	6:35	n.s.
Ch positive/negative	12:15	22:19	n.s.
Du positive/negative	14:13	20:21	n.s.
S positive/negative	12:15	16:25	n.s.
Rp positive/negative	16:11	28:13	n.s.
PV positive/negative	8:19	15:26	n.s.
A positive/negative	6:21	7:34	n.s.
PL positive/negative	9:18	19:2	n.s.
R grading 0:1:2 (n)	14:4:9	9:21:11	0.0040
R grading 0:1:2, %	52:15:33	22:51:27	
Radiological response*			
Grade Ia:Ib:II	12:6:9	N/E	

Data are expressed as the median (range).

Mod indicates moderately; por, poorly; other, papillary/adenosquamous cell carcinoma; R0, negative margin; R1, positive microscopic margin; R2, positive gross margin; LN met, lymph node metastasis; INF, mode of histological infiltration; Ly, grade of infiltration of the lymphatic vessels; V, grade of venous infiltration; Ne, grade of perineural invasion; Ch, grade of invasion to intrapancreatic common bile duct; Du, grade of invasion to the duodenum; S, grade of invasion to the anterior capsule; Rp, grade of invasion of the retroperitoneal tissue; Pv, grade of invasion of the portal vein; A, grade of invasion of the large artery; Pl, invasion of the extrapancreatic nerve plexus.

*Radiological response was defined as the amount of degenerated cancer cells.

Ia indicates less than 33% population of degenerated cancer cells; Ib, between 34% and 66%; II, more than 67%.

Follow-Up

After the completion of all treatments, patients were evaluated by physical examination every month, chest radiography, and CECT every 3 months. The development of a new low-density mass in the region of the pancreas bed and root of the mesentery was considered evidence of local recurrence even in the absence of symptoms. Cytological or histological confirmation of recurrent disease was not routinely required. Radiographic evidence of a new low-density region in the liver or lung was considered evidence of distant recurrence; biopsy was rarely performed. Peritoneal recurrence was defined as new ascites on physical examination or on CT and was confirmed by cytological examination of ascites. Sites of recurrent disease were documented at the time of initial recurrence. If the patients had any useful tumor markers at the first admission, these were checked again for confirmation of recurrence. In all patients, the date of first treatment was chosen as the starting point for survival analysis. All patients had a minimum follow-up of 25 months.

End Points and Statistical Analysis

The countable data were expressed as the median and range. The χ test or Fisher exact test was used for comparison of categorical variables when appropriate. The OS and DFS rates were calculated from the start of study treatment until death or the final date of follow-up and determined by the Kaplan-Meier method. Patients alive at the time of the study report were censored. The log-rank test was applied for the comparison of survival rates between different groups. Results were considered significant at $P < 0.05$.

RESULTS

Clinical Course of the NACRT Group

From 2001 to December 2004, 35 patients diagnosed as having pancreatic cancer were treated with NACRT using FP or GEM. Fourteen patients received FP-NACRT, and 21 patients received GEM-NACRT. According to NCCN guidelines, the 35 patients were divided into PR (n = 19) and borderline (n = 16), as shown in Figure 2. After NACRT, 34 patients were restaged using CECT or CE multidetector row CT, and 1 patient refused restaging. Three patients in the PR category (16%) did not undergo surgical resection because of liver metastasis, and 5 patients in the borderline category (31%) who had peritoneal metastasis (n = 2), liver metastasis (n = 1), and progressive disease (n = 1), in addition to 1 patient who refused restaging, did not undergo surgical resection. Finally, 16 patients (84%) in PR and 11 patients (69%) in borderline underwent surgical resection. The frequency of R0/1 in PR was 94%, significantly superior to 27% in borderline ($P < 0.0001$).

When radiological response was defined as the amount of degenerated cancer cells, only 9 patients (33%) in this NACRT regimen had more than 67% population of degenerated cancer cells (Table 1).

TABLE 3. Patient and Operative Factors in R0/1 Cases of the NACRT and Surgery-Alone Groups

	NACRT	Surgery-Alone	P
Total no. patients	18	30	
Age	65 (51–74)	68 (50 – 83)	n.s.
Gender (male/female)	7:11	18:12	n.s.
CA19-9, U/mL	90 (1–8116)	87 (1–9116)	n.s.
Comorbid disease (+/−)	10:8	18:12	n.s.
Site of primary lesion			
Head/body-tail	15:3	18:12	n.s.
Tumor size, mm	29 (16–80)	30 (13–90)	n.s.
PR/borderline	15:3	21:9	n.s.
Type of surgery (PD/TP/DP)	15:0:3	17:1:12	n.s.
PV resection (+/−)	3:15	9:21	n.s.
CA resection (+/−)	1:17	1:29	n.s.
Operative duration, min	557 (330–795)	512 (265–900)	n.s.
Extent of blood loss, mL	1078 (400–6420)	970 (390–5030)	n.s.

Data are expressed as the median (range).

Borderline indicates borderline resectable (NCCN, criteria defining resectability status); DP, distal pancreatectomy; LN, lymph node; PD, pancreaticoduodenectomy; PR potentially resectable; PV, portal vein; TP, total pancreatectomy.

TABLE 4. Tumor Factors in R0/1 Cases of the NACRT and Control Groups

	NACRT	Surgery Alone	P
Total no. patients	18	30	
Pathological differentiation (well:mod:por:other)	5:11:1:1	8:16:2:4	n.s.
Stage I-III/IVa/IVb	10:8	13:17	n.s.
LN met positive:negative	6:12	18:12	n.s.
INF β:γ	12:6	27:3	n.s.
Ly 0/1:2/3	12:6	11:19	n.s.
V 0/1:2/3	15:3	14:16	0.0158
Ne 0/1:2/3	5:13	4:26	n.s.
Ch positive/negative	8:10	13:17	n.s.
Du positive/negative	10:8	12:18	n.s.
S positive/negative	12:15	16:25	n.s.
Rp positive/negative	7:11	18:12	n.s.
PV positive/negative	2:16	8:22	n.s.
A positive/negative	1:17	2:28	n.s.
PL positive/negative	3:15	11:19	n.s.
Radiological response			
Grade Ia:Ib:II	7:4:7	N/E	

Data are expressed as the median (range).

Mod indicates moderately; por, poorly; other, papillary/adenosquamous cell carcinoma; LN met, lymph node metastasis; INF, mode of histological infiltration; Ly, grade of infiltration of the lymphatic vessels; V, grade of venous infiltration; Ne, grade of perineural invasion; Ch, grade of invasion to intrapancreatic common bile duct; Du, grade of invasion to the duodenum; S, grade of invasion to the anterior capsule; Rp, grade of invasion of the retroperitoneal tissue; Pv, grade of invasion of the portal vein; A, grade of invasion of the large artery; Pl, invasion of the extrapancreatic nerve plexus.

Comparisons of Surgical Results Between NACRT and Surgery-Alone Groups

The operative and tumor characteristics of all resected patients are listed in Tables 1 and 2. There were no significant differences in patient and operative characteristics between NACRT and surgery-alone groups. On comparison of tumor characteristics, significantly lower frequencies of lymph node metastasis, infiltration of lymphatic vessels, and venous infiltration in the NACRT group were found relative to those in the surgery-alone group ($P < 0.05$). Moreover, the frequency of pathologically curative resection (R0) in the NACRT group was significantly higher that that in the surgery-alone group (R0/1/2%, 52/15/33 vs 22/51/27; $P = 0.0040$). On abstracting R0/1 cases in NACRT and surgery-alone groups (Tables 3 and 4), although there was a tendency of a lower frequency of lymph node metastasis and infiltration of lymphatic vessels in the NACRT group relative to the surgery-alone group, a significant difference was not achieved. A significantly lower frequency of venous infiltration only was found in the NACRT group relative to the surgery-alone group ($P = 0.0158$). There was no difference in the survival curve of R2 cases between them.

Comparisons of OS and DFS Rates

All patients were followed up for at least 25 months without adjuvant chemotherapy. The median follow-up time after NACRT was 20.5 months (range, 3–84 months) for all patients and 56 months (range, 34–84 months) for censored patients. No



FIGURE 3. Overall survival rates in the NACRT and surgery-alone groups. Solid line indicates NACRT group; broken line, surgery-alone group. MST indicates median survival time.

treatment death occurred. Although the 1-, 3-, and 5-year OS rates in the NACRT group were 85%, 39%, and 34%, superior to 68%, 30%, and 9% in the surgery-alone group ($P = 0.0792$), there was no significant difference. The median survival time in the NACRT and surgery-alone groups was 24.5 and 18.5 months, respectively.

When patients who underwent curative resection (R0/1) were abstracted from all patients, there was a significant difference in the OS curve between the NACRT and surgery-alone groups (OS rates at 1 year, 3 years, and 5 years: 94%, 59%, and 52% in the NACRT group versus 83%, 34%, and 13% in the surgery-alone group; $P = 0.0425$; Fig. 3). The median survival time in the NACRT group was not reached, and in the surgery-alone group was 24 months. At a minimum of 36 months' follow-up, 8 patients in the NACRT group (44%) and 5 patients in the surgery-alone group (17%) were alive. Disease-free survival rates at 1 year, 3 years, and 5 years were 59%, 47%, and 47% in the NACRT group, significantly better than 53%, 12%, and 8% in the surgery-alone group (Fig. 4, $P = 0.0359$). Although the DFS rate at 1 year was similar, the difference in the DFS curve dramatically extended over 1 year after surgical resection. At the minimum follow-up of 25 months, 8 patients (44%) in the NACRT group and only 2 patients (7%) in the surgery-alone group were disease-free, and a significant difference was found between them ($P = 0.0024$). In the



FIGURE 4. Disease-free survival rates in the NACRT and surgery-alone groups. Solid line indicates NACRT group; broken line, surgery-alone group.

NACRT group, all patients disease-free for more than 1 year have survived between 36 and 65 months.

There were no significant differences in OS and DFS rates between the use of GEM- and 5-FU–based chemoradiation. Moreover, there was no significant difference in survival curves between patients with R0 and R1 resection.

Type of Recurrence in Patients Who Underwent Curative Resection (R0/1)

The major pattern of recurrence was distant metastasis such as the liver and peritoneum (39%) in the NACRT and local recurrence (47%) as well as distant metastasis (43%) in the surgery-alone group. The frequency of local recurrence in the NACRT group was 11%, significantly lower than 47% in the surgery-alone group ($P = 0.0024$).

DISCUSSION

Even after curative resection, patients with pancreatic cancer face a 50% to 80% local recurrence rate and a 25% to 50% chance of developing distant metastases at the peritoneum and liver. The dreadful prognosis associated with this disease has mandated studies of combined multimodality therapies with both radiation and chemotherapy.[11,12] Crane et al[13] mentioned that NACRT had its own intrinsic advantages in that it theoretically increased the vulnerability of cancer cells because of intact vasculature, better tumor cell oxygenation, and the probability of sterilizing cells at the resection margin. Neoadjuvant CRT can clinically provide improved patient selection because patients with rapidly progressive systemic disease are identified as part of the restaging evaluation performed after NACRT before the planned surgery. Another advantage is better tolerability, which consecutively allows multimodal treatment in a higher number of patients, and the avoidance of late radiation-related toxicity. Furthermore, NACRT is able to facilitate resectability with free margins and a low frequency of lymph node metastasis. The Duke University group[14] reported that NACRT was associated with a marked reduction in the incidence of pancreatic leak, as well as leak-associated morbidity and mortality. On the other hand, Tse et al[15] referred to the theoretical disadvantages of potential overtreatment for a subset of patients with early-stage disease or with benign disease and of the potential risk of biliary stent–related morbidity.

Our previous study demonstrated that 5-FU/CDDP- or GEM-based CRT could reduce pain at a high rate without affecting Karnofsky performance status and body weight, resulting in acceptable toxicity.[7] Subsequently, we attempted to compare surgical results after NACRT in patients with pancreatic cancer that extended beyond the pancreas with patients who underwent surgery alone in this study. As a result, a lower frequency of lymph node metastasis and a higher frequency of pathologically curative resection were observed in the NACRT group. In patients who underwent curative resection, OS and DFS rates in the NACRT group were significantly longer than in the surgery-alone group. At a minimum follow-up of 25 months, the actual DFS rate in the NACRT group was 44%, significantly better than 7% in the surgery-alone group. Moreover, the frequency of local recurrence in the NACRT group was significantly less than in the surgery-alone group.

Neoadjuvant CRT ultimately leads to patient selection, as patients who show tumor progression during chemoradiation do not undergo surgery. As many as approximately 20% to 40% of patients initially presenting with resectable pancreatic tumors, but which had become unresectable at restaging evaluation, avoided unnecessary laparotomy.[7,16–22] In this article, 16% of PR and 31% of borderline resectable patients in the NACRT group were excluded from the subsequent surgical resection.

In general, the favorable prognostic factors for survival and recurrence in patients with pancreatic cancer have been reported as curative resection and negative lymph node metastasis.[4,5] The quality of surgery and examination of the pathological specimens can vary. Raut et al[23] proposed the term *SMA margin*, which indicates perivascular soft tissue, primarily perineural and mesenteric tissue, adjacent to (and posterior to) the right lateral border of the proximal SMA. In pancreatic cancer, the retroperitoneal margin is very close and often positive. It seems reasonable to conclude that locoregional therapy in pancreatic cancer can be optimized with complete gross tumor resection and treatment of microscopic disease at the SMA margin with chemoradiation. Factors that define resectability include the surgeon's opinion on the necessity of venous or arterial resection and whether high-risk margins for tumor resection are acceptable. In this study, our surgical indication included not only "potentially resectable" but also "borderline resectable," defined by NCCN,[9] and subsequently, we allowed R2 resection in this study. We performed aggressive pancreatectomy with portal vein or CA resection in some cases in which resection had been predicted to generate surgical-free margins. During this study, surgical indication was fixed, and 2 experienced surgeons performed all resections. Two pathologists closely examined pathological specimens of the dependently removed surgical stump of perineural and retroperitoneal fat tissues between the pancreatic parenchyma and the SMA or CA under surgical exposition of the right-sided adventitia of the proximal SMA and CA. Some authors reported that the frequency of pathologically curative resection (R0) after NACRT was 60% to 90%,[7,16,17,19–23] which was similar to our results of 52% (69% in PR and 27% in borderline resectable cases). It has been reported that the frequency of negative lymph node metastasis after NACRT and surgical resection was 40% to 80%, lower than after surgery alone.[7,16,17,19,21,22] In this experience, 59% negative lymph node metastasis in the NACRT group was significantly higher than 32% in the surgery-alone group. Better patient selection and the direct effect of chemoradiation in the NACRT group are able to facilitate resectability with free margins and a low frequency of lymph node metastasis. On the other hand, 20 (29%) of 68 resected patients had R2 residual tumor staging. There were no differences in survival analysis between R2 surgery in the NACRT and surgery-alone groups. Although it is difficult to interpret the results in a small population, surgical results in R2 cases after NACRT were disappointing.

Previous studies have shown that surgery alone yielded local recurrence rates of 50% to 80%, whereas preoperative chemoradiation reduced local failure rates to 5% to 13%.[7,17,20–22,24] The low local recurrence rate (11%) in the NACRT group at a minimum follow-up of 25 months was encouraging and was similar to previous reports.[7,17,21,22] Interestingly, there was a similar DFS rate within 1 year in the NACRT and surgery-alone groups with the absence of adjuvant chemotherapy, but a significant difference of the DFS curve over 1 year was observed among those who underwent curative resection. When all observed patients were followed up for 2 years, 44% of patients in the NACRT group were disease-free, significantly better than 7% in the surgery-alone group. All surviving patients in the NACRT group have been disease-free with a range of follow-up of 36 and 65 months, and the median survival time in the NACRT group was not reached. Over time, the difference in the DFS curve was clearly extended. It is important to note that all patients did not undergo adjuvant

chemotherapy, but patients with recurrent disease underwent weekly GEM administration on recurrence.

The median survival time in 5-FU–based neoadjuvant trials ranged from 15.7 to 45 months, which compares favorably with the survival rate of patients in the observation arms of previous randomized adjuvant trials (range, 11–19 months),[25,26] and is similar to that of the treatment arms of randomized adjuvant trials (range, 20–44 months).[25,27,28] The M.D. Anderson Cancer Center group[29] reported favorable results that the median survival time in GEM-based chemoradiation was 33 months, and most patients were noted to have greater than 50% nonviable tumor cells in the specimen, and 2 pathological complete responses were noted. Moreover, a phase II trial of neoadjuvant GEM (400 mg/m^2) with concurrent radiation of 30 Gy showed that 61 (73%) of 71 patients underwent surgical resection, and the median survival time was 36 months at 2 years' follow-up.[30] A phase II multi-institutional trial of NACRT using full-dose GEM conducted at the University of Michigan[16] demonstrated that 17 of 20 patients underwent surgical resection with 94% R0 grading, and the median survival time and 2-year OS rate were 26 months and 61%, respectively, after a median follow-up of 18 months. Thus, some studies of NACRT have demonstrated favorable outcomes compared with similar series of patients treated with surgery alone; however, the efficacy results must be interpreted with caution because the reports of NACRT for pancreatic cancer are heterogeneous with regard to patient population, treatment methods, modalities, and limited accrual. The University of Liverpool group[27,31] criticized that some studies using NACRT resulted in a median survival time of 9 to 39 months, and the largest comparative study found that neither the survival nor the pattern of disease recurrence was significantly different between neoadjuvant and adjuvant therapy. There have been no randomized controlled trials of neoadjuvant therapy despite the positive outcomes of single-institutional series of neoadjuvant therapy. New trials are being developed to address the neoadjuvant therapy question.[32,33] Brunner et al[32] initiated a multicenter prospectively randomized phase II study that aimed to answer the question of whether NACRT with GEM and CDDP can prolong the OS of patients with ductal adenocarcinoma of the pancreatic head in comparison with primary resected patients.

Chemoradiation therapy followed by curative resection seems to improve survival in patients with pancreatic cancer that extended beyond the pancreas in this study; however, several questions remain controversial: Should therapy be given preoperatively or postoperatively? Which chemoagent with external radiation has the high efficacy to induce tumor cell necrosis? How long is needed? How much radiation and chemotherapy should be used? More effective and less toxic regimens are necessary for neoadjuvant therapy to realize the ultimate goal of maximizing the number of patients who receive curative resection with less frequent metastatic lymph nodes, resulting in 50% or more 5-year survival rates.

REFERENCES

1. White RR, Shah AS, Tyler DS. Pancreatic cancer since Halsted how far have we come and where are we going? *Ann Surg*. 2003;238: 132–144.
2. Willett CG, Lewandrowski K, Warshaw AL, et al. Resection margins in carcinoma of the head of the pancreas. Implications for radiation therapy. *Ann Surg*. 1993;217:144–148.
3. Chandler NM, Canete JJ, Stuart KE, et al. Preoperative chemoradiation in resectable pancreatic cancer. *J Hepatobiliary Pancreat Surg*. 2003;10:61–66.
4. Traverso LW. Pancreatic cancer: surgery alone is not sufficient. *Surg Endosc*. 2006;20:446–449.
5. Pingpank JF, Hoffman JP, Ross EA, et al. Effect of preoperative chemoradiotherapy on surgical margin status of resected adenocarcinoma of the head of the pancreas. *J Gastrointest Surg*. 2001;5:121–130.
6. Breslin TM, Hess KR, Harbison DB, et al. Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: treatment variables and survival duration. *Ann Surg Oncol*. 2001;8:123–132.
7. Takai S, Satoi S, Yanagimoto H, et al. Neoadjuvant chemoradiation in patients with potentially resectable pancreatic cancer. *Pancreas*. 2008;36:e26–e32.
8. National Comprehensive Cancer Network (NCCN) *Clinical Practice Guidelines in Oncology* 1:2005, Vol. 3, No. 5, 598.
9. Satoi S, Yamamoto H, Takai S, et al. Clinical impact of multidetector row computed tomography on patients with pancreatic cancer. *Pancreas*. 2007;34:175–179.
10. Satoi S, Yagagimoto H, Toyokawa H, et al. Preoperative patient selection of pancreatic cancer patients by multi-detector row CT and surgical results. *Hepatogastroenterology*. 2008. In press.
11. Wolff RA, Evans DB, Gravel DM, et al. Phase I trial of gemcitabine combined with radiation for the treatment of locally advanced pancreatic adenocarcinoma. *Clin Cancer Res*. 2001;7:2246–2253.
12. Takai S, Satoi S, Toyokawa H, et al. Clinicopathologic evaluation after resection for ductal adenocarcinoma of the pancreas: a retrospective, single-institution experience. *Pancreas*. 2003;26: 243–249.
13. Crane CH, Varadhachary G, Pisters PW, et al. Future chemoradiation strategies in pancreatic cancer. *Semin Oncol*. 2007;34:335–346.
14. Cheng TY, Sheth K, White RR, et al. Effect of neoadjuvant chemoradiation on operative mortality and morbidity for pancreaticoduodenectomy. *Ann Surg Oncol*. 2006;13:7–9.
15. Tse RV, Dawson LA, Wei A, et al. Neoadjuvant treatment for pancreatic cancer—a review. *Crit Rev Oncol Hematol*. 2008;65:263–274.
16. Talamonti MS, Small W Jr, Mulcahy MF, et al. A multi-institutional phase II trial of preoperative full-dose gemcitabine and concurrent radiation for patients with potentially resectable pancreatic carcinoma. *Ann Surg Oncol*. 2006;13:150–158.
17. Mornex F, Girard N, Scoazec JY, et al. Feasibility of preoperative combined radiation therapy and chemotherapy with 5-fluorouracil and cisplatin in potentially resectable pancreatic adenocarcinoma: the French SFRO-FFCD 97-04 Phase II trial. *Int J Radiat Oncol Biol Phys*. 2006;65:1471–1478.
18. Magnin V, Moutardier V, Giovannini MH, et al. Neoadjuvant preoperative chemoradiation in patients with pancreatic cancer. *Int J Radiat Oncol Biol Phys*. 2003;55:1300–1304.
19. White RR, Hurwitz HI, Morse MA, et al. Neoadjuvant chemoradiation for localized adenocarcinoma of the pancreas. *Ann Surg Oncol*. 2001;8:758–765.
20. Hoffman JP, Lipsitz S, Pisansky T, et al. Phase II trial of preoperative radiation therapy and chemotherapy for patients with localized, resectable adenocarcinoma of the pancreas: an Eastern Cooperative Oncology Group Study. *J Clin Oncol*. 1998;16:317–323.
21. Moutardier V, Magnin V, Turrini O, et al. Assessment of pathologic response after preoperative chemoradiotherapy and surgery in pancreatic adenocarcinoma. *Int J Radiat Oncol Biol Phys*. 2004;60:437–443.
22. Pisters PW, Wolff RA, Janjan NA, et al. Preoperative paclitaxel and concurrent rapid-fractionation radiation for resectable pancreatic adenocarcinoma: toxicities, histologic response rates, and event-free outcome. *J Clin Oncol*. 2002;20:2537–2544.
23. Raut CP, Tseng JF, Sun C, et al. Impact of resection status on pattern of failure and survival after pancreaticoduodenectomy for pancreatic adenocarcinoma. *Ann Surg*. 2007;246:52–60.
24. Pisters PW, Abbruzzese JL, Janjan NA, et al. Rapid-fraction

preoperative chemoradiation pancreatoduodenectomy, and intraoperative radiation therapy for resectable pancreatic adenocarcinoma. *J Clin Oncol.* 1998;16:3843–3850.

25. Kalser MH, Ellenberg SS. Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. *Arch Surg.* 1985;120:899–903.
26. Klinkenbijl JH, Jeekel J, Sahmoud T, et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC Gastrointestinal Tract Cancer Cooperative Group. *Ann Surg.* 1999;230:776–782.
27. Neoptolemos JP, Stocken DD, Friess H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. *N Engl J Med.* 2004;350:1200–1210.
28. Picozzi VJ, Traverso LW. The Virginia Mason approach to localized pancreatic cancer. *Surg Oncol Clin N Am.* 2004;13:663–674.
29. Evans DB. Preoperative chemoradiation for pancreatic cancer. *Semin Oncol.* 2005;32:25–29.
30. Wolff RA, Evans DB, Crane CH, et al. Initial results of a preoperative gemcitabine-based chemoradiation for resectable pancreatic adenocarcinoma. *Proc Am Soc Clin Oncol.* 2002;21:130a [abstract 516].
31. Ghaneh P, Smith R, Tudor-Smith C, et al. Neoadjuvant and adjuvant strategies for pancreatic cancer. *Eur J Surg Oncol.* 2007; 11;1–9.
32. Brunner TB, Grabenbauer GG, Meyer T, et al. Primary resection versus neoadjuvant chemoradiation followed by resection for locally resectable or potentially resectable pancreatic carcinoma without distant metastasis. A multi-centre prospectively randomised phase II-study of the Interdisciplinary Working Group Gastrointestinal Tumours (AIO, ARO, and CAO). *BMC Cancer.* 2007;7:41.
33. Crane CH, Varadhachary G, Wolff RA, et al. The argument for pre-operative chemoradiation for localized, radiographically resectable pancreatic cancer. *Best Pract Res Clin Gastroenterol.* 2006;20: 365–382.

Minimally Invasive Therapy. 2009;18:311–314

informa
healthcare

CASE REPORT

Transcatheter coil embolization of an aneurysm of an anomalous splenic artery: Usefulness of double microcatheter method

NOBORU TANIGAWA[1], SHUJI KARIYA[1], HIROYUKI KOJIMA[1], TAKANORI TOKUDA[1], ATSUSHI KOMEMUSHI[2], SATOSHI SAWADA[1]

[1]*Department of Radiology, Kansai Medical University, Hirakata Hospital, Osaka, Japan* [2]*Department of Radiology, Kansai Medical University, Takii Hospital, Osaka, Japan*

Abstract

Transcatheter embolization using two microcatheters of different shapes was performed to treat a 34-mm-diameter aneurysm that was located near the origin of a splenic artery that originated from the superior mesenteric artery (SMA). The procedure resulted in complete packing of the aneurysm and preserving splenic arterial blood flow.

Key words: *Aneurysm, splenic artery, anomaly, embolization, coils*

Introduction

Aneurysms of the splenic artery are the most common splanchnic aneurysms. However, aneurysms of a splenic artery with an anomalous origin from the superior mesenteric artery (SMA) are rare (1–11). Only 14 such cases were identified during a literature search of English-language reports. Of these 14 cases, only two cases were treated with interventional technique (1,2).

Case report

The patient was a 45-year-old male hepatitis B carrier. The patient had annual abdominal ultrasound examinations for the past five years. The most recent ultrasound showed an aneurysm that was located posterior to the pancreatic head. Reconstructed three-dimensional images (Figure 1) based on contrast-medium-enhanced computed tomographic scans obtained by 16-detector CT (Siemens, Erelangen, Germany) showed that the splenic artery had an anomalous origin from the SMA, and that a saccular dilatation of the splenic artery was located 2 mm distal to the origin. A diagnosis of a splenic artery aneurysm was made. The splenic artery aneurysm was 34 mm in diameter and had an aneurysmal neck diameter of 8 mm. No calcification was seen in the wall. Since the patient had been undergoing annual abdominal ultrasound examinations, and this was the first time that an arterial aneurysm had been identified, this implied that the aneurysm had enlarged rapidly. Given this, and that the diameter of the aneurysm was > 30 mm, and that the aneurysmal wall had no calcification, it was concluded that treatment was absolutely indicated. After discussion with a vascular surgeon and an interventional radiologist, percutaneous embolization was selected as the treatment of choice. The procedure was performed after written informed consent was obtained from the patient.

First, a Cobra guiding catheter with an inner diameter of 0.081 inches and an outer diameter of 7 French (Mach 1, Boston Scientific, Watertown, MA, USA) was inserted into the ostium of the SMA via the right femoral artery, and arteriography was performed (Figure 2). Two 2.5 French microcatheters (Renegade-18, Boston Scientific) were then prepared; steam was used to shape one of the microcatheters whose tip was bent to an angle of 60°. The straight microcatheter and the microcatheter bent to an angle of 60° were inserted through the guiding catheter to different sites in the aneurysm (Figure 3). Twenty detachable 30-cm long microcoils (Cook Inc., Bloomington, IN, USA) were

Correspondence: N. Tanigawa, Department of Radiology, Kansai Medical University, Hirakata Hospital, 2-3-1 Shinmachi, Hirakata, Osaka, 573-1191 Japan, E-mail: tanigano@hirakata.kmu.ac.jp

ISSN 1364-5706 print/ISSN 1365-2931 online
DOI: 10.1080/13645700903201365



Figure 1. Three-dimensional reconstructed image based on contrast medium-enhanced computed tomographic scans obtained using a 16-detector CT. The splenic artery originating from the SMA and a saccular aneurysm in the splenic artery immediately distal to the origin can be seen.



Figure 2. Left anterior oblique view (45°) obtained during the superior mesenteric arteriogram. A broad-necked arterial aneurysm is seen in the splenic artery, whose origin is the SMA.

inserted using one of the microcatheters. At the time of the insertion of the 21st detachable 30-cm long microcoil, this coil was seen in the main splenic artery. Then the coils were seen in the main splenic artery, the insertion of coils from this microcatheter was stopped, and the detachable coils (6 25-cm-long microcoils; and



Figure 3. Intraoperative plain X-ray. Two microcatheters have been inserted to different locations in the aneurysm. Detachable coils are being inserted using one of the catheters, while the tip of the other microcatheter can be seen in the aneurysm (→).

10 20-cm long microcoils) were then inserted using the other microcatheter. In this manner, the entire arterial aneurysm was packed. Finally, the two microcatheters were removed, and arteriography was performed using the guiding catheter, which remained in the SMA. On arteriography, no contrast medium flowed into the aneurysm, and the blood flow in the SMA and splenic artery was found to be preserved. Therefore, the procedure was completed (Figure 4). The following microcoils were used: 24 detachable 30-cm long microcoils; six 25-cm-long microcoils; and ten 20-cm long microcoils. The patient had no complications after the procedure, such as pain or fever, and was discharged on the next day. Plain abdominal X-ray examination performed three months after the embolization procedure showed no change in the location of the coils and no coil compaction (Figure 5). Contrast CT performed three months after embolization showed that the main splenic artery was patent; no findings indicative of splenic infarction were noted (Figure 6).

Discussion

Reports of arterial aneurysms occurring in a splenic artery originating from the SMA are very rare (1–11). Only 14 such cases were identified on a literature search of English-language reports. The reported treatment methods used in these 14 cases included:



Figure 4. Postoperative superior mesenteric arteriogram. The inside of the aneurysm is completely packed with microcoils; blood flow in the main splenic artery is maintained.

Figure 5. Plain abdominal X-ray, frontal view, obtained three months after embolization. No coil migration or compaction is seen.

Surgical treatment in 11 cases (2–6, 8–11); transcatheter coil packing of the arterial aneurysm combined with laparoscopic splenic arterial ligation in two cases (7); and coil embolization alone in two cases (1,2). Of the two cases in which coil embolization alone was done, the procedure involved packing alone in one case (1), and packing and isolation in the other case (2). In



Figure 6. Contrast abdominal CT done three months after embolization. There is no evidence of splenic infarction.

the case reported by Sato, in which packing alone was used, the neck of the aneurysm was narrow, the diameter of the aneurysm was 25 × 23 mm, and the distance from the origin of the artery to the aneurysm was short, as in our case. In the case reported by Migliara et al., in which both packing and isolation were used, the distance from the origin of the splenic artery to the aneurysm was relatively long (25 mm); after packing had been performed within the aneurysm, additional coil embolization was performed in the main splenic artery at the center of the aneurysm and distal to the aneurysm.

In the present case, the distance from the origin of the splenic artery to the aneurysm was short (2 mm), and blood flow through the SMA was preserved. Therefore, it was thought that aneurysm isolation or the placement of a cover stent in the main splenic artery where the aneurysm was located would be difficult. However, since the aneurysm was saccular and had a neck diameter of 8 mm, it was determined that it would be possible to perform coil packing and preserve splenic artery blood flow.

Since the diameter of the aneurysm in the present case was 34 mm, which was larger than the aneurysm diameters in the two cases previously reported and described above, in order to ensure that packing was uniform throughout the entire aneurysm, coil packing was done using two catheters with tips of different shapes. If only a single microcatheter had been used to insert a large number of coils, the coils would have escaped into the parent vessel before aneurysm packing could have been completed. Therefore, two microcatheters with tips of different shapes were inserted through the parent catheter to different aneurysm sites. Then, coils were inserted from one of these

microcatheters. When it appeared that coils were about to escape into the main splenic artery, coil embolization was continued using the other microcatheter. This enabled the aneurysm to be sufficiently packed with coils without coils escaping into the main splenic artery.

In conclusion, coil embolization using two microcatheters with different tip shapes was done to treat a very large, 34-mm-diameter, arterial aneurysm that was located in a splenic artery originating from the SMA. The procedure allowed the aneurysm to be successfully packed while preserving splenic arterial blood flow.

References

1. Sato M, Anno I, Yamaguchi M, Iida H, et al. Splenic artery aneurysm of the anomalous splenomesenteric trunk: successful treatment by transcatheter embolization using detachable coils. Cardiovasc Intervent Radiol. 2006;29:432–4.
2. Migliara B, Lipari G, Mansueto GC, Riva F, et al. Managing anomalous splenic artery aneurysm: a review of the literature and report of two cases. Ann Vasc Surg. 2005;19:546–52.
3. Illuminati G, LaMuraglia G, Nigri G, Vietri F. Surgical repair of an aberrant splenic artery aneurysm: report of a case. Ann Vasc Surg. 2007;21:216–8.
4. Settembrini PG, Jausseran JM, Roveri S, et al. Aneurysms of anomalous splenomesenteric trunk: clinical features and surgical management in two cases. J Vasc Surg. 1996;24: 687–92.
5. Ghatan JD, Beranbaum ER, Bowles LT, Veith FJ. Aneurysm of anomalous splenic artery. Ann Surg. 1967;166:144–6.
6. Patel P, Turner PJ, Curley PJ. Reconstruction of the SMA after excision of an anomalous splenic artery aneurysm. Eur J Vasc Endovasc Surg. 1998;15:369–70.
7. Mastracci TM, Cadeddu M, Colopinto RF, Cina C. A minimally invasive approach to the treatment of aberrant splenic artery aneurysms: a report of two cases. J Vasc Surg. 2005;41: 1053–7.
8. Facy O, Naouri A, Dugas B, Kadji M, et al. Aneurysm of the splenic artery arising from the superior mesenteric artery: therapeutic management. Ann Chir 2006;131:401–4. Epub 2006 Feb 14. French.
9. LaBella GD, Muck P, Kasper G, Welling R, et al. Operative management of an aberrant splenic artery aneurysm: Utility of the medial visceral rotation approach: a case report and review of the literature. Vasc Endovascular Surg. 2006;40: 331–3.
10. Tochii M, Ogino H, Sasaki H, et al. Successful surgical treatment for aneurysm of splenic artery with anormalous origin. Ann Thorac Cardiovasc Surg. 2005;11:346–9.
11. Sidhu PS, Khaw KT, Belli AM. Anomalous splenic artery aneurysm: demonstration on CT scanning and angiography. Postgrad Med J. 1995;71:49–51.

Cardiovasc Intervent Radiol (2009) 32:1059–1066
DOI 10.1007/s00270-009-9510-1

TECHNICAL NOTE

Development of a New Subclavian Arterial Infusion Chemotherapy Method for Locally or Recurrent Advanced Breast Cancer Using an Implanted Catheter–Port System After Redistribution of Arterial Tumor Supply

Kenji Takizawa · Hiroshi Shimamoto · Yukihisa Ogawa · Misako Yoshimatsu · Kunihiro Yagihashi · Yasuo Nakajima · Takashi Kitanosono

Received: 4 August 2008 / Accepted: 8 January 2009 / Published online: 24 February 2009

Abstract Locally or recurrent advanced breast cancers can receive arterial blood supply from various arteries, such as the internal thoracic artery (ITA), the lateral thoracic artery, and the other small arterial branches originating from the subclavian artery. Failure to catheterize and subsequent formation of collateral arterial blood supply from various arteries are some of the reasons why the response to conventional selective transarterial infusion chemotherapy is limited and variable. To overcome this problem, we developed a new subclavian arterial infusion chemotherapy method using an implanted catheter–port system after redistribution of arterial tumor blood supply by embolizing the ITA. We named this technique ("redistributed subclavian arterial infusion chemotherapy" (RESAIC)). Using RESAIC, patients can be treated on an outpatient basis for extended periods of time. Eleven patients underwent RESAIC, and the complete remission and partial response rate in 10 evaluable patients was 90%: complete remission [CR] $n = 4$, partial remission $n = 4$, stable disease $n = 1$, and not evaluable $n = 1$. Three of four patients with CR had no distant metastasis, and modified radical mastectomy was performed 1 month after conclusion of RESAIC. The resected specimens showed no residual cancer cells, and pathologically confirmed complete remission was diagnosed in each of these cases. Although temporary grade-3 myelosuppression was seen in three patients who were previously treated by systemic chemotherapy, there was no other drug-induced toxicity or procedure-related complications. RESAIC produced a better response and showed no major complications compared with other studies despite the advanced stage of the cancers.

Keywords Interventional Radiology · Breast cancer · Arterial infusion chemotherapy · Implanted port

K. Takizawa (✉) · H. Shimamoto · Y. Ogawa · M. Yoshimatsu · K. Yagihashi · Y. Nakajima
Department of Radiology, St. Marianna University School of Medicine, Sugao, Miyamae, Kawasaki, Kanagawa, Japan
e-mail: taki-lrl@vy.catv.ne.jp

H. Shimamoto
e-mail: hshima@k8.dion.ne.jp

Y. Ogawa
e-mail: yukky-p406c@nifty.com

M. Yoshimatsu
e-mail: misako_yosh@yahoo.co.jp

K. Yagihashi
e-mail: yagiku@hotmail.com

Y. Nakajima
e-mail: y3naka@marianna-u.ac.jp

T. Kitanosono
Department of Vascular/Interventional Radiology, University of Rochester Medical Center, 601 Elmwood Avenue, Box 648, Rochester, NY, USA
e-mail: tkita1@mac.com

Introduction

Locally or recurrent advanced breast cancers (ABC) are defined as large tumors with extensive regional lymph node involvement or direct invasion of the skin or underlying chest wall [1]. These cancers are considered stages IIIa and IIIb according to the tumor-node-metastasis classification system adopted by the Japanese Breast Cancer Society, which is based on the classification system of the International Union Against Cancer [2]. Inflammatory breast cancer showing extensive histologic infiltration of dermal lymphatics is a distinct subset.

Some previous reports showed that arterial infusion chemotherapy (AIC) was effective for ABC [3–5]. The local response rate was reported to be 70–90%, and rapid tumor regression was seen after the treatment [6–10]. However, problems associated with AIC should be resolved as will be described later. Conventionally in AIC procedures, the chemotherapeutic agents are selectively infused into subclavian and axillary branches supplying the tumor. This procedure is technically complicated and is usually repeated multiple times in each patient. In addition, such repeated infusions cause drug-induced damage to the infused arterial branches, and this promotes the development of collateral arterial blood supply [11, 12]. Therefore, the number of possible repetitions of AIC is limited, and long-term local control is not expected. To overcome this problem, we developed a new subclavian arterial infusion chemotherapy method using an implanted catheter–port system (CPS) after redistribution of the arterial blood supply to the tumor. The arterial redistribution was achieved by embolizing the internal thoracic artery (ITA) using a mixture of N-butyl cyanoacrylate (NBCA; B. Braun, Melsungen, Germany) and iodized oil (LPD) (Lipiodol Ultra-Fluide; Terumo, Tokyo, Japan) [13, 14]. Using this drug-delivery system, patients can be treated on an outpatient basis for extended periods of time. We believe that this new technique, named "redistributed subclavian arterial infusion chemotherapy" (RESAIC), is an epoch-making treatment method that, to the best of our knowledge, has not been reported previously. This study was an initial pilot study evaluating the effectiveness and safety of RESAIC.

Patients and Methods

Patients with ABC whose tumors were resistant to standard systemic chemotherapy or who were physically unable to tolerate systemic chemotherapy were the subjects of this study. In addition, patients >70 years of age with no previous treatment were also included. Eligibility criteria included histologically confirmed carcinoma of the breast, a life expectancy >2 months, World Health Organization performance status <3, adequate bone marrow reserve (white blood cell count >2500/ml, platelet count >50,000/ml), satisfactory renal and liver function (total bilirubin and creatinine <1.25 times the upper normal limits), and normal cardiac function by electrocardiogram (ECG). Any previous systemic chemotherapy except trastuzumab (Herceptin; Chugai, Japan) was discontinued for at least 4 weeks before protocol entry. Trastuzumab was continued to inhibit the development of distant metastases. Eleven patients were entered into this study between April 2006 and December 2007. All patients were female and had diagnosed stage IIIb or IV disease. A 52-year-old woman who had severe anemia (hemoglobin 5.6 g/dl) caused by bleeding from the primary tumor was entered because she was considered unable to tolerate standard systemic chemotherapy. All patients gave informed consent to participate in the trial. Table 1 shows demographics of the participating patients. The patients' ages ranged from 39 to 82 years (median of 61).

All patients were histologically diagnosed as having invasive ductal carcinoma, and one of the patients showed

Table 1 Patient's characteristics

Patient no.	Age	Tumor	Neoadjuvant or resistant	Stage	Distal metastasis	Symptom	Pathology	ER	PgR	Her2
1	58	Primary	Resistant	IV	Lung, liver	Pain	IDC/scirrhous carcinoma	+	+	1+
2	39	Primary	Resistant	IV	Lung, bone	Pain, ulcer, bleeding	IDC/papillo-tubular carcinoma	−	−	−
3	51	Recurrence	Resistant	IV	Lung, bone	Pain, ulcer, bleeding	IDC/scirrhous carcinoma	+	+	2+
4	52	Primary	Neoadjuvant	IIIb	−	Pain, bleeding, effusion	IDC	−	−	2+
5	72	Primary	Resistant	IIIb	−	Pain, ulcer, effusion	IDC	+	+	−
6	61	Recurrence	Resistant	IV	Liver	Pain, ulcer, effusion, arm edema	IDC/solid-tubular carcinoma	+	−	−
7	81	Primary	Neoadjuvant	IIIb	−	Pain, ulcer, effusion, arm edema	IDC	−	−	2+
8	78	Recurrence	Resistant	IIIb	−	Pain, erosion, induration	IDC (inflammatory breast cancer)	−	−	2+
9	70	Primary	Neoadjuvant	IV	Lung, bone	Pain, ulcer, bleeding, arm edema	IDC/scirrhous carcinoma	+	+	2+
10	82	Recurrence	Resistant	IV	Lung, liver	Pain, bleeding	IDC/solid-tubular carcinoma	+	−	−
11	52	Primary	Resistant	IV	Lung, liver, brain	Pain, bleeding, abscess formation	IDC/solid-tubular carcinoma	−	−	3+

IDC invasive ductal carcinoma

inflammatory breast cancer. Four patients had no distant metastasis. Three patients were previously untreated (neoadjuvant group) and eight were resistant to the previous systemic chemotherapy (resistant group). One patient had undergone mastectomy, and another patient had undergone radiotherapy. Overall tumor size ranged from 5.9 to 21.3 cm in diameter (median 10.5), from 10.5 to 13.9 cm (median 12.2) in the neoadjuvant group, and from 5.9 to 21.3 cm (median 6.7) in the resistant group. Tumor stages in the neoadjuvant group were IIIB in two patients and IV in one patient, and the stages in the resistant group were IIIB in two patients and IV in six patients.

Implantation of the CPS for RESAIC was performed by way of angiography with the patient under local anesthesia. First, embolization of the ITA was performed. In the first case, the ITA was embolized initially by way of a transfemoral approach. This was followed by implantation of the CPS by way of a brachial artery approach, and the port was placed in a subcutaneous pouch at the forearm (two-route method). In the other 10 patients, both embolization and implantation of the CPS were achieved with the ipsilateral brachial approach (one-route method). In the one-route method, the brachial artery was punctured at the level of the elbow joint, and a 4F 11-cm sheath was inserted. Subsequently, selective arteriograms of the subclavian artery and the internal thoracic artery were obtained with a 4F cobra-shaped catheter, a 4F pigtail catheter, or a hook-shaped catheter inserted through the sheath (Fig. 1A, B). Thereafter, embolization of the ITA was performed by a coaxial technique. To embolize the peripheral levels, a mixture of NBCA, which was diluted eight times with LPD (NBCA–LPD), was infused by way of a microcatheter advanced to approximately 3 cm distal to the tip of the parent catheter. To describing the procedure in more detail, the tip of the parent catheter was advanced up to the first corner of the ITA, and the tip of the microcatheter was further advanced to approximately 3 cm distal to the corner. The tip was placed in the straight-line part of the ITA. In eight cases, the proximal portion of the ITA was additionally embolized using one or two Tornado microcoils (Cook), 3–5 or 3–6 mm in diameter. After the embolization was confirmed with repeat arteriogram, implantation of the CPS was commenced (Fig. 1C, D). A long tapered Anthron-PU catheter (AP) with a distal shaft measuring 3.3F and 60 cm long and a proximal shaft measuring 5F and 40 cm long) was placed as an indwelling catheter with its tip positioned just distal to the ITA over a 0.025-inch guidewire. Before insertion, the length of the tapered 3.3F part of the AP was shortened to match the length from the puncture site to the placement site measured on the fluoroscopic monitor. The length ranged from 30 to 37 cm (median 32.4). After insertion of the AP, the distal end of the catheter was connected to a port (brachial type of Celsite port; Toray, Japan) and was implanted at the subcutaneous pouch approximately 5 cm distal to the puncture site in the forearm through the subcutaneous tunnel (Fig. 1E).

Treatment

To prevent perfusion to the arm, a sphygmomanometer cuff was used during injection of anticancer drugs. To evaluate drug distribution over the entire tumor, computed axial tomography arteriography (CTA) was performed while contrast material was infused by way of the implanted CPS. Drug distribution was evaluated in the most recent eight patients, except for one who had inflammatory breast cancer within the first treatment cycle of the protocol. CTA was started 30 seconds after injection of 30 ml contrast material, 50% diluted with saline, at a speed of 0.5 ml/s.

Bolus injections of anticancer agents were repeated weekly. Epirubicin (EP), 30 mg/body diluted with 20 ml distilled water, was injected during the implantation of the CPS as an initial treatment. From the second treatment onward, a treatment cycle consisted of cisplatin (10 mg/body) and 5-fluorouracil (5-FU) (750 mg/body) on days 1 and 8 and 15, and EP (20 mg/body) on days 22 of treatment. Both cisplatin and 5-FU were diluted with 20 ml normal saline, and EP was diluted with 20 ml distilled water. For two patients (patients no. 8 and 11), who had been treated with trastuzumab before undergoing our treatment, EP was excluded from the treatment protocol because of potential cardiac toxicity. In these patients, cisplatin (50 mg/body) and 5-FU (1000 mg/ body) were used at the initial injection instead of EP. Both drugs were diluted with normal saline, 100 and 20 ml, respectively. From the second treatment onward, the same doses of cisplatin and 5-FU were again injected. The drugs were injected at a speed of 1 ml/5 s for 60 seconds, and then the tourniquet was removed to reperfuse the arm for 30 seconds. This treatment cycle was repeated until all of the drugs were delivered for a particular session.

A decrease in leukocyte count <2,500 or platelet count <50,000 prompted us to interrupt the treatment until the counts increased. At leukocyte counts ranging from 2,500 to 3,000 or at platelet counts ranging from 50,000 to 100,000, the dosage of 5-FU was decreased to 500 mg/body. Cycles were repeated until sufficient regression was achieved. Blood counts and biochemistry tests were monitored weekly.

Treatment-related responses in the primary site tumors and regional lymph node metastases were evaluated by the change in the largest diameter of the lesion using the *Response Evaluation Criteria in Solid Tumors* (RECIST) manual [15]. Herein, measurable lesions are defined as tumors that can be measured accurately in at least one



Fig. 1 (**A**) Digital subtraction angiography of subclavian artery by way of brachial approach in patient number 5 shows dilated internal and lateral thoracic arteries supplying advanced breast cancer. (**B**) A selective internal thoracic arteriogram was obtained using a 4F hook-shaped catheter. The medial part of the tumor is markedly opacified. (**C**) After embolization of the ITA using NBCA-LPD, a subclavian arteriogram was obtained by injection of contrast material by way of the indwelling catheter. The absence of opacification of the ITA was confirmed. (**D**) The scout film demonstrates the tip of the indwelling catheter (*white arrow*) placed just distal to the ITA as well as the accumulation of the infused NBCA-LPD (*white arrow heads*). (**E**) The distal end of the catheter was connected to the port and implanted at the subcutaneous pouch approximately 5 cm distal to the puncture site in the forearm through the subcutaneous tunnel. (**F**) Pretreatment CAT shows a huge tumor occupying the right-sided anterior chest wall. (**G**) CAT examination 1 month after starting RESAIC demonstrates a marked decrease in tumor size. Multiple high-density dots represent accumulation of NBCA-LPD in the ITA (*white arrow*) and its branches. (**H**) CAT examination 3 months later shows disappearance of the tumor. CR was diagnosed

dimension as being ≥10 mm and with a diameter that is more than twice the slice thickness (5 mm) by computed axial tomography (CAT) or magnetic resonance imaging (MRI). All measurable lesions, up to a maximum of 5, should be identified as target lesions, and these lesions should be selected in order of tumor size, starting with the largest.

Ten patients, except the one who had inflammatory breast cancer, were evaluated. Complete response (CR) was defined as disappearance of all target lesions. Partial response (PR) was defined as at least a 30% decrease in the sum of the largest diameters of the target lesions, using the baseline sum of the largest diameters as reference. Progressive disease (PD) was defined as at least a 20% increase in the sum of the largest diameters of the target lesions, using the baseline sum of the largest diameters as reference. Stable disease (SD) was defined as neither shrinkage sufficient to qualify for PR nor increase sufficient to qualify for PD. Not evaluable (NE) was defined when an evaluation by CT or MRI could not be done. CT and MRI scans were examined monthly. After the conclusion of RESAIC, clinical follow-up was carried out every 3 months. Procedure-related complications and treatment were scaled using version 3 of the National Cancer Institute's Common Terminology Criteria for Adverse Events [16].

Results

There were no serious procedure-related complications during CPS implantation nor were there any complications related to CPS during treatment. Two patients had grade 2 chest pain for a few days after embolization of ITA, but they had no visible dermal injury on the anterior chest wall, and the symptoms subsided without intervention. All patients were discharged within a few days after the procedure and continued infusions on an outpatient basis. The observation periods ranged from 90 to 553 days (average 310). Eight patients belonging to the resistant group required a dose-reduction of 5-FU because of decreased blood cell counts. Temporary grade-3 myelosuppression was seen in three patients belonging to the resistant group, requiring interruption of RESAIC for 2 weeks and administration of granulocyte colony-stimulating factor (G-CSF). The number of treatment cycles ranged from 3 to 10 (average 4.7), and the number of days when CPS was used ranged from 85 to 258 days (average 147.5).

The results of RESAIC are listed in Table 2. Nine of 10 (90%) patients showed PR or CR. The size of the tumor in one patient with inflammatory breast cancer could not be accurately measured on CT or MRI. In responder patients, at least some tumor reduction was observed within 1 treatment cycle. In three of four CR patients, resected specimens showed no residual cancer cells, and pathologic complete remission (PCR) was diagnosed in each of them. They have been alive and tumor free for 14, 9, and 2 months, respectively (Fig. 1F–H). The treatment of another CR patient in the resistant group with distant metastases was discontinued after 6 treatment cycles, and the patient was transferred to best supportive care after radiotherapy because of progression of her metastatic disease. The treatment of one patient with SD was discontinued after the patient had received 3 treatment cycles because of progression of lung metastasis. One patient (no. 3) with PR refused >3 treatment cycles because her preprocedural depression became worse. One patient who had inflammatory breast cancer underwent 5

Table 2 Treatment results

Patient no.	Treatment cycle	Beginning tumor size (cm)	Ending tumor size (cm)	Local response	Observation period (d)	Outcome
1	10	6.2	3.0	PR	553	Dead from metastasis
2	3	6.6	5.0	SD	351	Dead from metastasis
3	3	5.9	2.9	PR	141	Dead from metastasis
4	3	13.9	Scar	CR	539	Surgery → tumor free (14 mo)
5	5	6.8	Scar	CR	546	Surgery → tumor free (9 mo)
6	4	12.7	Scar	CR	373	Radiation, hepatic arterial chemotherapy
7	5	10.5	Scar	CR	252	Surgery → tumor free (2 mo)
8	5	–	–	NE	226	Observation
9	5	12.2	5.0	PR	192	Systemic chemotherapy
10	5	21.3	7.5	PR	144	Continuing SAIC
11	3	6.8	2.2	PR	90	Continuing SAIC

treatment cycles and had no exacerbation for 3 months after discontinuation of RESAIC. The treatment of one patient with PR (initial group) was interrupted after 5 treatment cycles because of bone metastasis progression. She was followed-up by systemic chemotherapy with aromatase inhibitors and capecitabine (Zeroda; Chugai, Japan). Currently, two patients have undergone RESAIC without complication. Entire tumors in the breast and axillary regions were remarkably enhanced on CTA in each of the eight patients examined. Even the recurrent tumor present in the medial portion of the chest wall after mastectomy was enhanced and responded to RESAIC (Fig. 2A–C). Symptoms-such as pain caused by skin ulceration, bleeding, foul odor, arm edema, or paresthesia-improved in all patients. The improvement of bleeding and pain was apparent a few days after the initial infusion, and arm edema improved as tumor size decreased.

All patients initially developed grade 1 skin hyperpigmentation in the infused areas ranging from the anterior chest wall to the back. Grade-1 alopecia occurred in two patients. The local symptoms improved, and RESAIC was continued on an outpatient basis without any significant complications in any patient.

Discussion

Currently, neoadjuvant systemic chemotherapy followed by local therapy is considered the standard treatment for controlling both local and inherent disseminated disease in patients with ABC [17]. However, an optimal chemotherapeutic regimen, local therapy, and optimal sequencing of those modalities have not been determined. Patients with ABC often suffer from symptoms, such as pain, bleeding, foul odor associated with infection, arm edema, or paresthesia. Therefore, preserving quality of life with local sterilization is given priority in such patients. AIC has often been applied as neoadjuvant chemotherapy for stage III tumors for the purpose of tumor downstaging [7, 8], as locoregional control of recurrent cancer [9], or as palliation [10]. In addition, it has been reported that AIC was feasible and effective in elderly patients [10]. However, selective and repeated infusion using the conventional procedure cause drug-induced damage of the infused arterial branches, and this promotes the development of a collateral arterial supply. Anatomically, the posterior intercostal and inferior epigastric arteries communicate to the anterior intercostal and superior epigastric arterial branches of the



Fig. 2 (**A**) Pretreatment CTA of the patient number 6 shows a huge tumor metastasis in the right axillary region. Another metastatic tumor with ring enhancement (*white arrow*) is seen on the medial side of the anterior chest wall. (**B**) Pretreatment subclavian arteriogram by way of the implanted CPS demonstrates a huge tumor, which is mainly supplied by the lateral thoracic artery in the right axillary region. The *black arrow* represents embolized coils in the ITA. (**C**) CTA obtained by infusion of contrast material by way of the implanted CPS at the time of the third infusion chemotherapy demonstrates decreased sizes of both tumors and contrast enhancement of the tumors, which represents distribution of the infused drug

ITA. Therefore, it is reasonable to suppose that these arteries participate in the collateral arterial blood supply. Hence, the infused drug cannot be delivered to the entire tumor while AIC is being repeated. The number of possible repetitions of AIC is limited, and long-term local control cannot be expected. To deliver the infused drug efficiently to the entire tumor through a single implanted catheter–port system for an extended period of time, we developed RESAIC. The technical key point of RESAIC is the arterial redistribution of the subclavian artery achieved by ITA embolization using NBCA-LPD. This technique converges the multiple supplying arteries into a single subclavian arterial supply, thus inhibiting development of the collateral arteries. Drug distribution by CTA was satisfactory in all patients examined. The polymerization time of the mixture of NBCA diluted 8 times with LPD takes at least $\geq$10 seconds [18]. After which, the mixture was appropriate to embolize the peripheral levels of ITA in all patients. It is essential that NBCA-LPD is injected by way of a coaxial system relatively slowly, i.e., for approximately 10 seconds, to avoid problems associated with NBCA-LPD, such as migration or catheter fixation.

Many studies on AIC have reported that chemotherapy regimens, including anthracycline and 5-FU with or without other drugs, were efficient in downstaging ABC [3, 4, 6, 7, 10]. That is the reason why the regimens including EP and 5-FU, plus low-dose CDDP to modulate 5-FU, were designed.

Local chemoinfusion through a redistributed blood supply produced an overall response rate of 90%. Four patients had CR, and three of them showed PCCR. Two of the three patients who belonged to the neoadjuvant group had PCR, and the other patient had PR during treatment. Local symptoms improved, and RESAIC was continued on an outpatient basis in all patients without any significant complications. None of the patients had complications related to brachial arterial flow disturbance or cerebrovascular ischemia despite the long-term implantation of CPS. However, patients with a high risk of thromboembolism may need concomitant anticoagulation therapy. The drug must be infused slowly to prevent anticancer agents and potential thrombi from flowing out into the vertebral artery.

Our response rate was potentially higher than those reported in previous conventional AIC reports. Among them were a few reports on AIC using CPS [19, 20]. In these reports, the indwelling catheter was placed into the ITA or subclavian artery without arterial redistribution. Compared with our method, the number of infusion repeats were fewer, and the CR rate was lower (only 1 of 18 patients) [19].

In conclusion, RESAIC had a better response rate and no major complications compared with other studies despite the advanced stage of the cancer. Our results suggest that RESAIC is a reasonable and efficient locoregional treatment for ABC in elderly patients or in those who cannot physically tolerate chemotherapy, and it is available for patients with ABC who are resistant to systemic chemotherapy.

Because of our encouraging results, further larger-scale studies are needed in the near future to evaluate whether RESAIC is a treatment option that can improve local symptoms and prolong good quality of life in patients with ABC, even if RESAIC does not contribute to prolonged survival.

References

1. Haagensen CD (1986) Clinical classification of the stage of advancement of breast carcinoma. In: Haagensen CD (ed) Disease of the breast. W B Saunders, Philadelphia, pp 851–863
2. Japanese Breast Cancer Society (1989) The general rules for clinical and pathological recording of breast cancer. Jpn J Surg 19: 612–632
3. Murakami M, Kuroda Y, Nishimura S, Sano A, Okamoto Y, Taniguchi T et al (2001) Intraarterial infusion chemotherapy and radiotherapy with or without surgery for patients with locally advanced or recurrent breast cancer. Am J Clin Oncol 24:185–191
4. Kitagawa K, Yamakado K, Nakatsuka A, Tanaka N, Matsumura K, Takeda K et al (2002) Preoperative transcatheter arterial infusion chemotherapy for locally advanced breast cancer (stage IIIb) for down-staging and increase of resectability. Eur J Radiol 43:31–36
5. Fiorentini G, Tsetis D, Bernardeschi P, Varveris C, Rossi S, Kalogeraki A et al (2003) First-line intra-arterial chemotherapy (IAC) with epirubicin and mitoxantrone in locally advanced breast cancer. Anticancer Res 23:4339–4345
6. Koyama H, Wada T, Takahashi Y, Iwanaga T, Aoki Y (1975) Intra-arterial infusion chemotherapy as preoperative treatment of locally advanced breast cancer. Cancer 36:1603–1612
7. Stephens FO (1990) Intraarterial induction chemotherapy in locally advanced stage III breast cancer. Cancer 66:645–650
8. Görich J, Hasan I, Majdali R, Sittek H, Kunze V, Doma A, ET AL (1995) Previously treated, locally recurrent breast cancer: treatment with superselective intraarterial chemotherapy. Radiology 197: 199–203
9. Bufill JA, Grace WR, Neff R (1994) Intra-arterial chemotherapy for palliation of fungating breast cancer. A case report and review of the literature. Am J Clin Oncol 17:118–124
10. Pacetti P, Mambrini A, Paolucci R, Sanguinetti F, Palmieri B, Della Seta R, ET AL (2006) Intra-arterial chemotherapy: a safe treatment for elderly patients with locally advanced breast cancer. In Vivo 20:761–764
11. Seki H, Kimura M, Yoshimura M, Yamamoto S, Ozaki T, Sakai K (1998) Development of extrahepatic arterial blood supply to the liver during hepatic arterial infusion chemotherapy. Eur Radiol 8: 1613–1618
12. Ymagami T, Kato T, Tanaka O, Hirota T, Nishimura T (2005) Influence of extrahepatic arterial inflow into the posterior segment or caudate lobe of the liver on repeated hepatic arterial infusion chemotherapy. JVIR 16:457–463
13. Arai Y, Inaba Y, Takeuchi Y (1997) Interventional techniques for hepatic arterial infusion chemotherapy. In: Castaneda-Zuniga WR (ed) Interventional radiology, 2nd edn. Williams & Wilkins, Baltimore, pp 192–205
14. Yamagami T, Kato T, Iida S, Tanaka O, Nishimura T (2004) Value of transcatheter arterial embolization with coils and n-butyl cyanoacrylate for long-term hepatic arterial infusion chemotherapy. Radiology 230:792–802

15. Padhani AR, Ollivier L (2001) The RECIST (response evaluation criteria in solid tumors) criteria: implications for diagnostic radiologists. Br J Radiol 74:983–986
16. Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V et al (2003) CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 13:176–181
17. Wang HC, Lo SS (1996) Future prospects of neoadjuvant chemotherapy in treatment of primary breast cancer. Semin Surg Oncol 12:59–66
18. Stoesslein F, Ditscherlein G, Romaniuk PA (1982) Experimental studies on new liquid embolization mixtures (histoacryllipiodol, histoacryl-panthopaque). Cardiovasc Intervent Radiol 5:264–267
19. Cakmakli S, Ersöz S, Tug T, Karaayvaz M, Akgül H (1997) Intra-arterial infusion chemotherapy in the treatment of locally advanced breast cancer. Acta Oncol 36:489–492
20. Grosso M, Zanon C, Mancini A, Garruso M, Gazzera C, Anselmetti GC et al (2000) Percutaneous implantation of a catheter with subcutaneous reservoir for intraarterial regional chemotherapy: technique and preliminary results. Cardiovasc Intervent Radiol 23: 202–210